| Related Articles |
Lisdexamfetamine Dimesylate — Benefit Assessment According to §35a Social Code Book V
Book. 2013 08 29
Authors: Institute for Quality and Efficiency in Health Care
Abstract
The aim of this report was to assess the added benefit of lisdexamfetamine as part of a comprehensive treatment programme for attention deficit / hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate, in comparison with the appropriate comparator therapy (ACT) atomoxetine. In accordance with the Federal Joint Committee, the company cited atomoxetine as ACT for lisdexamfetamine, which is indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. The benefit assessment of lisdexamfetamine was conducted in comparison with atomoxetine. The assessment was conducted based on patient-relevant outcomes and on direct comparative randomized controlled trials (RCTs).
PMID: 27905759
via https://www.ncbi.nlm.nih.gov/pubmed/27905759?dopt=Abstract